Skip to main content
Top
Published in: Journal of Medical Case Reports 1/2021

Open Access 01-12-2021 | Case report

Alpha 2-antiplasmin deficiency in a Sudanese child: a case report

Author: Bashir Abdrhman Bashir Mohammed

Published in: Journal of Medical Case Reports | Issue 1/2021

Login to get access

Abstract

Background

The plasma serine protease inhibitor alpha 2-antiplasmin (α2-AP, otherwise known as α2-plasmin inhibitor) is a rapid-acting plasmin inhibitor recently found in human plasma, which seems to have a significant role in the regulation of in vivo fibrinolysis. Congenital deficiency of α2-AP is extremely uncommon.

Case presentation

We report here a case of absolute deficiency of α2-AP in an 11-year-old Sudanese boy, who had a lifelong intermittent hemorrhagic tendency (gum bleeding, epistaxis, and exaggerated bleeding after trauma). Coagulation tests including prothrombin time, partial thromboplastin time, thrombin time, bleeding time, platelet count, clot retraction test, antithrombin, and factor VIII levels were within normal limits. Hepatic function tests and complete blood count were also normal. The main interesting finding in this patient was that the whole blood clot lysis was extremely fast, completed within 5–8 hours. The second abnormal finding is that the euglobulin clot lysis time was short. Nevertheless, the concentration of α2-AP in the patient's plasma was 0.2 IU/ml (reference range is 0.80–1.20 IU/ml). The addition of pooled plasma (with normal α2-AP) to the patient's whole blood corrected the accelerated fibrinolysis.

Conclusion

The study showed that α2-AP deficiency resulted in uninhibited fibrinolysis that caused the hemorrhagic tendency in this patient. Thus, this report demonstrates the significant role of α2-AP in coagulation.
Literature
1.
go back to reference Carpenter SL, Mathew P. Alpha2-antiplasmin and its deficiency: fibrinolysis out of balance. Haemophilia. 2008;14:1250–4.CrossRef Carpenter SL, Mathew P. Alpha2-antiplasmin and its deficiency: fibrinolysis out of balance. Haemophilia. 2008;14:1250–4.CrossRef
2.
go back to reference Reed GL, Houng AK, Singh S, Wang D. Alpha2-antiplasmin: new insights and opportunities for ischemic stroke. SeminThrombHemost. 2017;43(2):191–9. Reed GL, Houng AK, Singh S, Wang D. Alpha2-antiplasmin: new insights and opportunities for ischemic stroke. SeminThrombHemost. 2017;43(2):191–9.
3.
go back to reference Abdul S, Leebeek FW, Rijken DC, Willige SU. Natural heterogeneity of alpha2-antiplasmin: functional and clinical consequences. Blood. 2016;127(5):538–45.CrossRef Abdul S, Leebeek FW, Rijken DC, Willige SU. Natural heterogeneity of alpha2-antiplasmin: functional and clinical consequences. Blood. 2016;127(5):538–45.CrossRef
4.
go back to reference Gebhart J, Kepa S, Hofer S, Koder S, Kaider A, Wolberg AS, Haslacher H, Quehenberger P, Eigenbauer E, Panzer S, Mannhalter C, Pabinger I. Fibrinolysis in patients with a mild-to-moderate bleeding tendency of unknown cause. Ann Hematol. 2017;96:489–95.CrossRef Gebhart J, Kepa S, Hofer S, Koder S, Kaider A, Wolberg AS, Haslacher H, Quehenberger P, Eigenbauer E, Panzer S, Mannhalter C, Pabinger I. Fibrinolysis in patients with a mild-to-moderate bleeding tendency of unknown cause. Ann Hematol. 2017;96:489–95.CrossRef
5.
go back to reference Saes JL, Schols SEM, van Heerde WL, Nijziel MR. Hemorrhagic disorders of fibrinolysis: aclinical review. J Thromb Haemost. 2018;16:1498–509.CrossRef Saes JL, Schols SEM, van Heerde WL, Nijziel MR. Hemorrhagic disorders of fibrinolysis: aclinical review. J Thromb Haemost. 2018;16:1498–509.CrossRef
6.
go back to reference Rijken DC, Uitte de Willige S. Inhibition of fibrinolysis by coagulation factor XIII. Biomed Res Int. 2017;2017:1209676.CrossRef Rijken DC, Uitte de Willige S. Inhibition of fibrinolysis by coagulation factor XIII. Biomed Res Int. 2017;2017:1209676.CrossRef
7.
go back to reference Igala M, Oukkach B, Khoubila N, Faez S, Benchekroun S. A congenital alpha2-antiplasmin deficiency. Ann Biol Clin. 2013;71:93–5. Igala M, Oukkach B, Khoubila N, Faez S, Benchekroun S. A congenital alpha2-antiplasmin deficiency. Ann Biol Clin. 2013;71:93–5.
8.
go back to reference Yasar Yildiz S, Kuru P, Toksoy Oner E, Agirbasli M. Functionalstability of plasminogen activator inhibitor-1. Sci World J. 2014;2014:858293.CrossRef Yasar Yildiz S, Kuru P, Toksoy Oner E, Agirbasli M. Functionalstability of plasminogen activator inhibitor-1. Sci World J. 2014;2014:858293.CrossRef
9.
go back to reference Hirose J, Takedani H, Kubota M, Kinkawa J, Noguchi M. Total hip arthroplasty and total knee arthroplasty in a patientwith congenital deficiency of plasminogen activator inhibitor-1. Haemophilia. 2016;22:e237–9.CrossRef Hirose J, Takedani H, Kubota M, Kinkawa J, Noguchi M. Total hip arthroplasty and total knee arthroplasty in a patientwith congenital deficiency of plasminogen activator inhibitor-1. Haemophilia. 2016;22:e237–9.CrossRef
10.
go back to reference Iwaki T, Tanaka A, Miyawaki Y, Suzuki A, Kobayashi T, Takamatsu J, Matsushita T, Umemura K, Urano T, Kojima T, Terao T, Kanayama N. Life-threatening hemorrhage and prolonged wound healing are remarkable phenotypes manifested bycomplete plasminogen activator inhibitor-1 deficiency inhumans. J ThrombHaemost. 2011;9:1200–6.CrossRef Iwaki T, Tanaka A, Miyawaki Y, Suzuki A, Kobayashi T, Takamatsu J, Matsushita T, Umemura K, Urano T, Kojima T, Terao T, Kanayama N. Life-threatening hemorrhage and prolonged wound healing are remarkable phenotypes manifested bycomplete plasminogen activator inhibitor-1 deficiency inhumans. J ThrombHaemost. 2011;9:1200–6.CrossRef
Metadata
Title
Alpha 2-antiplasmin deficiency in a Sudanese child: a case report
Author
Bashir Abdrhman Bashir Mohammed
Publication date
01-12-2021
Publisher
BioMed Central
Published in
Journal of Medical Case Reports / Issue 1/2021
Electronic ISSN: 1752-1947
DOI
https://doi.org/10.1186/s13256-021-02813-6

Other articles of this Issue 1/2021

Journal of Medical Case Reports 1/2021 Go to the issue